Abstract
In vivo exposure with response prevention is the current gold-standard treatment for anxiety disorders. However, many patients respond insufficiently. Given the involvement of CB1 receptors in conditioned fear extinction, influencing CB1 receptor signaling through the phytocannabinoid cannabidiol (CBD) may enhance treatment effects. We tested this hypothesis in a multi-site, outpatient, parallel randomized, double-blind, placebo-controlled fixed dose clinical trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
